Statistiche di base
| LEI | 549300NN5KFIEHPECJ85 |
| CIK | 1474167 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cosmos Health Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2025 (August 7, 2025) COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Co |
|
| August 11, 2025 |
Form of 9% Original Issue Discount Senior Secured Convertible Promissory Note. EXHIBIT 4.1 FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, AC |
|
| August 6, 2025 |
Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy EXHIBIT 99.1 Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy CHICAGO, IL / GLOBE NEWSWIRE / August 6, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional invest |
|
| August 6, 2025 |
Form of Registration Rights Agreement, dated as of August 5, 2025. EXHIBIT 10.3 Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 5, 2025, is by and among Cosmos Health Inc., a Nevada corporation with offices located at 141 West Jackson Boulevard, Suite 4236, Chicago IL 60604 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connecti |
|
| August 6, 2025 |
Form of Voting and Support Agreement, August 5, 2025. EXHIBIT 10.4 Execution Version VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”), dated as of August 5, 2025 (the “Effective Date”), by and among Cosmo Health Inc., a Nevada corporation (the “Company”), and certain stockholders of the Company as listed on Schedule A hereto (each, a “Stockholder” and, collectively, the “Stockholders”). RECITALS WHEREAS, on August 5, |
|
| August 6, 2025 |
Form of Securities Purchase Agreement, dated as of August 5, 2025. EXHIBIT 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 5, 2025, is by and among Cosmos Health Inc., a Nevada corporation with offices located at 141 West Jackson Boulevard, Suite 4236, Chicago IL 60604 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” an |
|
| August 6, 2025 |
Form of Security and Pledge Agreement, dated as August 5, 2025. EXHIBIT 10.2 EXECUTION VERSION SECURITY AND PLEDGE AGREEMENT SECURITY AND PLEDGE AGREEMENT, dated as of August 5, 2025 (this “Agreement”), made by Cosmos Health Inc., a Nevada corporation, with offices located at 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604, United States (the “Company”), and each of the direct and indirect Domestic Subsidiaries (as defined below) of the Company, if any, f |
|
| August 6, 2025 |
Form of Account Control Agreement, August 5, 2025. EXHIBIT 10.5 Account Control Agreement This Account Control Agreement (the “Agreement”) is made effective August 5, 2025 among Cosmos Health Inc., a Nevada corporation (the “Pledgor”), [*], a [*] (in its capacity as collateral agent for the Buyers (as defined below) in such capacity, together with its successors and assigns in such capacity, the “Secured Party”), [*] (“Delegate”), for the limited |
|
| August 6, 2025 |
Form of 9% Original Issue Discount Senior Secured Convertible Promissory Note. EXHIBIT 4.1 [FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE] NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2025 (August 5, 2025) COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Co |
|
| June 3, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 3, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 3, 2025 Registration Statement No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registran |
|
| May 7, 2025 |
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq EXHIBIT 99.1 Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq CHICAGO, IL / ACCESSWIRE / May 6, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, an |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2025 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as |
|
| April 15, 2025 |
EXHIBIT 21 SUBSIDIARIES Name Jurisdiction Ownership Cosmofarm Ltd. Greece 100 % SkyPharm, S.A. Greece 100 % Decahedron Ltd. United Kingdom 100 % ZipDoctor Inc. Texas 100 % Cana Laboratories Holding (Cyprus) Limited Cyprus 100 % |
|
| April 15, 2025 |
Insider Trading Policies and Procedures EXHIBIT 19.1 INSIDER TRADING POLICY 1. General Purpose Federal securities laws prohibit the purchase or sale of securities by persons who are aware of material non-public information about a company, as well as the disclosure of material, non-public information about a company to others who then trade in the company’s securities. These transactions are commonly known as “insider trading.” Insider |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit |
|
| February 18, 2025 |
Cosmos Health Announces It Will Not Proceed with an Offering Under Its Form S-1 EXHIBIT 99.1 Cosmos Health Announces It Will Not Proceed with an Offering Under Its Form S-1 CHICAGO, IL / ACCESSWIRE / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthca |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2025 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| February 7, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 7, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 7, 2025 Registration Statement No. |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 28, 2025 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 29, 2025 |
EXHIBIT 99.1 Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow CHICAGO, IL / ACCESSWIRE / January 28, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company’’) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pha |
|
| January 22, 2025 |
Patent and Technology License Agreement EXHIBIT 10.1 PATENT AND TECHNOLOGY LICENSE AGREEMENT This Patent and Technology License Agreement ("Agreement") is made on December 31, 2024 (the “Effective Date”) by and between DOCPHARMA Single SA. (“Licensor”), a Greek company, located at Agiou Georgiou 5, 57001, Pylaia, Greece, and COSMOS HEALTH INC., a Nevada corporation, located at 141 West Jackson Boulevard, Suite 4236, Chicago IL 60604 ("L |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2024 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| January 14, 2025 |
Consent of Davidoff Hutcher & Citron LLP (included in Exhibit 5.1)** AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 14, 2025 Registration Statement No. |
|
| January 14, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| January 10, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 8, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 8, 2025 Registration Statement No. |
|
| January 6, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 6, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 6, 2025 Registration Statement No. |
|
| December 18, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| December 18, 2024 |
Form of Common Warrant issued in connection with this offering EXHIBIT 4.9 FORM OF WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HEALTH INC. Warrant Shares: Issue Date: December , 2024 Initial Exercise Date: [•], THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| December 18, 2024 |
Form of Placement Agent Agreement EXHIBIT 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 December , 2024 Cosmos Health Inc. 5 Agiou Gergiou, Pilea Thessaloniki, Greece 55438 Attention: Grigorios Siokas, Chief Executive Officer Re: Placement Agency Agreement Dear Mr. Siokas: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, |
|
| December 18, 2024 |
9,748,252 Shares of Common Stock FILED PURSUANT TO RULE 424(b)(3) REGISTRATION STATEMENT NO. 333-282859 Prospectus 9,748,252 Shares of Common Stock This prospectus relates to the resale (the “Offering”) by Armistice Capital Master Fund, Ltd. (the “Selling Shareholder”) of up to 9,748,252 shares of Common Stock, $0.001 par value, of Cosmos Health Inc. (the “Company,” “Cosmos” or “we”) issuable upon exercise of warrants to purchase |
|
| December 18, 2024 |
Form of Pre‑Funded Warrant issued in connection with this offering EXHIBIT 4.8 FORM OF PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HEALTH INC. Warrant Shares: Original Exercise Date: December , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for |
|
| December 18, 2024 |
EXHIBIT 10.97 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December , 2024, between Cosmos Health Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| December 18, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 18, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 18, 2024 Registration Statement No. |
|
| December 12, 2024 |
COSMOS HEALTH, INC. 5 Agiou Georgiou Pilea Thessaloniki, Greece 55438 COSMOS HEALTH, INC. 5 Agiou Georgiou Pilea Thessaloniki, Greece 55438 December 12, 2024 Division of Corporation Finance Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Alyssa Wall Re: Cosmos Health, Inc. Form S-1 Registration StatementFile No. 333-282859 Dear Ms. Wall: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cosmos Health, |
|
| December 10, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 10, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 10, 2024 Registration Statement No. |
|
| November 27, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 27, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 27, 2024 Registration Statement No. |
|
| November 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 19, 2024 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of regis |
|
| November 14, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 14, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 14, 2024 Registration Statement No. |
|
| November 14, 2024 |
COSM / Cosmos Health Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-cosm093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cosmos Health Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 221413305 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2024 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| October 28, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| October 28, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 28, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 28, 2024 Registration Statement No. |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| September 27, 2024 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 27, 2024 |
Form of Inducement Offer Letter between Cosmos Health Inc. and A.G.P./Alliance Global Partners (73) EXHIBIT 10.1 COSMOS HEALTH INC. 2 Agiou Georgiou Pilea, Thessaloniki Greece 55438 September 26, 2024 To the Holder of Warrants to Purchase Shares of Common Stock of Cosmos Health Inc. Issued on December 28, 2023 Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: COSMOS HEALTH INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “yo |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2024 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| September 27, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 17, 2024 |
6,936,996 Shares of Common Stock COSMOS HEALTH INC. FILED PURSUANT TO RULE 424(b)(3) REGISTRATION STATEMENTS: No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 Prospectus 6,936,996 Shares of Common Stock COSMOS HEALTH INC. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CO |
|
| September 17, 2024 |
6,936,996 Shares of Common Stock COSMOS HEALTH INC. FILED PURSUANT TO RULE 424(b)(3) REGISTRATION STATEMENTS: No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 Prospectus 6,936,996 Shares of Common Stock COSMOS HEALTH INC. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CO |
|
| September 17, 2024 |
6,936,996 Shares of Common Stock COSMOS HEALTH INC. 424B3 1 cosm424b3.htm 424B3 FILED PURSUANT TO RULE 424(b)(3) REGISTRATION STATEMENTS: No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 Prospectus 6,936,996 Shares of Common Stock COSMOS HEALTH INC. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. |
|
| September 17, 2024 |
6,936,996 Shares of Common Stock COSMOS HEALTH INC. FILED PURSUANT TO RULE 424(b)(3) REGISTRATION STATEMENTS: No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 Prospectus 6,936,996 Shares of Common Stock COSMOS HEALTH INC. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CO |
|
| September 5, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-276755 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-269289 POST-EFFECTIVE AMENDMENT NO. 1 t |
|
| September 5, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-276755 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-269289 POST-EFFECTIVE AMENDMENT NO. 1 t |
|
| September 5, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-276755 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-269289 POST-EFFECTIVE AMENDMENT NO. 1 t |
|
| September 4, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 4, 2024 No. 333-276755 No. 333-269289 No. 333-274093 No. 333-267550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-276755 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 Registration Statement No. 333-269289 POST-EFFECTIVE AMENDMENT NO. 1 t |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registran |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as |
|
| August 5, 2024 |
EXHIBIT 21 SUBSIDIARIES Name Jurisdiction Ownership Cosmofarm Ltd. Greece 100 % SkyPharm, S.A. Greece 100 % Decahedron Ltd. United Kingdom 100 % ZipDoctor Inc. Texas 100 % Cana Laboratories Holding (Cyprus) Limited Cyprus 100 % |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 22, 2024 |
EXHIBIT 99.1 Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule CHICAGO, IL / ACCESSWIRE / July 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and |
|
| May 28, 2024 |
EXHIBIT 99.1 Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufactur |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| May 3, 2024 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) |
|
| May 2, 2024 |
EXHIBIT 16.1 |
|
| May 2, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) |
|
| May 2, 2024 |
Response Letter from Cosmos Health Inc. to KPMG* EXHIBIT 16.2 May 1, 2024 By electronic mail TO: KPMG Certified Auditors S.A. 44 Syngrou Avenue 117 42 Athens, Greece Dear KPMG Certified Auditors S.A., The Board of Directors of Cosmos Health Inc. ("Cosmos" or the "Company") and its Audit Committee have reviewed your letter dated April 29, 2024, which was provided to the Company for purposes of being filed as Exhibit 16.1 to the Amendment of the C |
|
| April 26, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 25, 2024 |
Form Rights Agreement and Rights Certificate (74) EXHIBIT 4.1 RIGHTS AGREEMENT RIGHTS AGREEMENT, dated as of April 22, 2024 (this “Agreement”) by and between Cosmos Health Inc., a Nevada corporation (the “Company”), and Globex Transfer, LLC, as rights agent (the “Rights Agent”); WHEREAS it has been determined that it is in the best interests of the Company to adopt a shareholder rights plan to ensure, to the extent possible, that all shareholders |
|
| April 25, 2024 |
Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 17, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 19, 2024 |
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K EXHIBIT 99.1 Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. (“Cosmos Health” or the “Company’’) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, a |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit |
|
| March 22, 2024 |
RELATED PARTY TRANSACTION POLICIES AND PROCEDURES EXHIBIT 99.1 RELATED PARTY TRANSACTION POLICIES AND PROCEDURES POLICY It is the policy of the Board of Directors (“Board”) of Cosmos Health Inc. (“Company”) that all Related Party Transactions, as that term is defined in this policy (“Policy”), shall be subject to review in accordance with the procedures set forth below. The Board has determined that the Audit Committee (“Committee”) is best suite |
|
| March 22, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 7, 2024 |
COSMOS HEALTH INC. Up to $6,900,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-267550 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED DECEMBER 15, 2022 AND PROSPECTUS SUPPLEMENT DATED FEBRUARY 29, 2024 COSMOS HEALTH INC. Up to $6,900,000 Shares of Common Stock This prospectus supplement updates and amends certain information in the prospectus, dated December 15, 2022 (the “Base Prospectus”) as supplemented by the pros |
|
| February 29, 2024 |
COSMOS HEALTH INC. 5,049,535 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-267550 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED DECEMBER 15, 2022 COSMOS HEALTH INC. 5,049,535 Shares of Common Stock We are offering on a “reasonable best efforts” basis up to 5,049,535 of shares of common stock of Cosmos Health Inc. (the “Common Stock”). This offering is made pursuant that certain Sales Agreement, or sales agreemen |
|
| February 15, 2024 |
COSMOS HEALTH INC. 4,874,126 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-274093 PROSPECTUS COSMOS HEALTH INC. 4,874,126 Shares of Common Stock This prospectus relates to the sale (the “Offering”) by Armistice Capital Master Fund, Ltd. (the “Selling Shareholder”) of up to 4,874,126 shares of Common Stock, $0.001 par value, of Cosmos Health Inc. (the “Company,” “Cosmos” or “we”) issuable upon exercise of war |
|
| February 14, 2024 |
DE:V67A / Cosmos Health Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2024 |
COSMOS HEALTH INC. 5 AGIOU GEORGIOU PILEA THESSALONIKL, GREECE 55428 February 6, 2024 COSMOS HEALTH INC. 5 AGIOU GEORGIOU PILEA THESSALONIKL, GREECE 55428 February 6, 2024 Division of Corporation Finance Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attention: Scott Anderegg Re: Cosmos Health Inc. Form S-3 Registration Statement File No. 333-276755 Dear Mr. Anderegg, Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cosmo |
|
| January 29, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 29, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 29, 2024 Registration Statement No. |
|
| January 29, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| January 22, 2024 |
EXHIBIT 99.1 Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. (“Cosmos Health” or the “Company’’) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufa |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 18, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 27, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| December 29, 2023 |
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 EXHIBIT 99.1 Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 · In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor. · These acquisitions are projected to contribute almost $4 million in incremental group annual revenue in FY 2023. · Projected FY 2024 group revenue from these acqu |
|
| December 29, 2023 |
Form of Warrant Exchange Agreement (71) EXHIBIT 4.2 COSMOS HEALTH INC. 2 Agiou Georgiou Pilea, Thessaloniki Greece 55438 December 28, 2023 To the Holder of Warrants to Purchase Shares of Common Stock of Cosmos Health Inc. Issued on July 21, 2023 and December 21, 2022 Re: Warrant Exchange Agreement Dear Holder: COSMOS HEALTH INC. (the “Company”) is pleased to offer (this “Offer”) to you (“Holder”, “you” or similar terminology) the opport |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 27, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) |
|
| December 29, 2023 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 28, 2023 |
EXHIBIT 10.1 Cosmos Health Inc. (“the Company”) CLAWBACK POLICY Introduction The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2023 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| November 22, 2023 |
EXHIBIT 99.1 Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 /Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pha |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☒ Transi |
|
| October 10, 2023 |
COSMOS HEALTH CEO Issues Letter to Shareholders EXHIBIT 99.1 COSMOS HEALTH CEO Issues Letter to Shareholders · Company reaches major strategic inflection point, with operations and revenue ramp-up underway, to significantly accelerate in 2024 and beyond · Maintains solid balance sheet with negligible debt and strong, diversified asset base · Book value exceeds $4 per share, which is more than 2.5x current share price · Tangible assets, includin |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 18, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| September 14, 2023 |
EXHIBIT 99.1 Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023 ● Company reaches major strategic inflection point, with operations and revenue ramp-up underway ● Inaugural 2026 guidance introduced; target to achieve: ○ More than $180 million in gross annual revenue ○ EBITD |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| August 31, 2023 |
COSMOS HEALTH INC. 1,935,485 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-274093 PROSPECTUS COSMOS HEALTH INC. 1,935,485 Shares of Common Stock This prospectus relates to the sale (the “Offering”) by selling shareholders (the “Selling Shareholders”) of up to 1,935,485 shares of common stock, $0.001 par value (the “Shares”), of Cosmos Health Inc. (the “Company,” “Cosmos” or “we”) issuable upon exercise of Co |
|
| August 29, 2023 |
COSMOS HEALTH INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 COSMOS HEALTH INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 August 29, 2023 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Kate Beukenkamp Re: Cosmos Health Inc. Form S-3 Registration Statement File No. 333-274093 Dear Ms. Beukenkamp: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| August 18, 2023 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 18, 2023 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 18, 2023 Registration Statement No. |
|
| August 18, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as spec |
|
| August 15, 2023 |
EXHIBIT 99.1 Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04 CHICAGO, IL / August 15, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of prop |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☒ Transition |
|
| August 7, 2023 |
EXHIBIT 16.1 Armanino LLP 2700 Camino Ramon Suite 350 San Ramon, CA 94583-5004 925 790 2600 main 925 790 2601 fax armanino.com August 7, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of the Current Report on Form 8-K of Cosmos Health Inc. dated August 7, 2023, which we understand will be filed with the Securities and Exchang |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 25, 2023 |
Form of Securities Purchase Agreement(70) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 20, 2023, between Cosmos Health Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| July 25, 2023 |
US2214132068 / COSMOS HOLDINGS INC / Siokas Grigorios - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) COSMOS HOLDINGS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 221413206 (CUSIP Number) Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158 (Name, Address and Telephone Num |
|
| July 25, 2023 |
Form of Investor Agreement(70) EXHIBIT 10.3 INVESTOR AGREEMENT July 20, 2023 This agreement (the “Investor Agreement”) is being delivered to you in connection with an understanding by and between Cosmos Health Inc., a Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby made to (a) the Securities Purchase Agreement, dated July 20, 202 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 25, 2023 |
EXHIBIT 99.1 Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private Placement CHICAGO, IL / ACCESSWIRE / July 20, 2023 / Cosmos Health Inc. (the “Company”) (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that i |
|
| July 25, 2023 |
EXHIBIT 99.2 Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement CHICAGO, IL / ACCESSWIRE / July 21, 2023 / Cosmos Health Inc. (the “Company”) (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the cl |
|
| July 25, 2023 |
Form of Pre-Funded Warrant(70) EXHIBIT 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HEALTH INC. Warrant Shares: Original Exercise Date: July , 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t |
|
| July 25, 2023 |
Form of Amendment No. 1 to Common Warrant Agreement(70) EXHIBIT 10.4 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of July 21, 2023, by and between Cosmos Health Inc., a Nevada corporation (the “Company”), and (the “Holder”). WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant, issued as of , to purchase shares of common stock of the Company, |
|
| July 25, 2023 |
Form of Placement Agency Agreement(70) EXHIBIT 10.2 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 July 20, 2023 Cosmos Health Inc. Attention: Grigorios Siokas, Chief Executive Officer 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 Re: Placement Agency Agreement Dear Mr. Siokas: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners |
|
| July 25, 2023 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 21, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-269289 Prospectus Supplement (To the Prospectus dated January 27, 2023) COSMOS HEALTH INC. 782,610 Shares of Common Stock Issuable Upon the Exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated January 27, 2023 (the “Prospectus”), relating to the resale by two |
|
| July 21, 2023 |
PROSPECTUS SUPPLEMENT (to the Prospectus dated December 15, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| July 6, 2023 |
Cosmos Health Successfully Completes Acquisition of Cana Laboratories; EXHIBIT 99.1 Cosmos Health Successfully Completes Acquisition of Cana Laboratories; Anticipates to Record a Substantial Gain on Bargain Purchase CHICAGO, IL / ACCESSWIRE / July 6, 2023 / Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and med |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 31, 2023 |
EXHIBIT 10.1 BINDING LETTER OF INTENT (LOI) This Letter of Intent (“LOI”) sets forth the terms and conditions for a proposed acquisition and financing by Cosmos Health Inc. (“Cosmos”), a corporation organized under the laws of the State of Nevada, with Company I.R.S number (27-0611758),located at 141 West Jackson Boulevard, Suite 4236, Chicago, IL 60604, of Docpharm Gmbh. (the “Company” or “docpha |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as spe |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 11, 2023 |
EXHIBIT 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), dated as of May 8, 2023, is entered into between by and among Cosmos Health Inc., a Nevada corporation (“Buyer”) and Konstantinos-Gaston Kanaroglou, an individual, and Konstantina-Mathilde Kanaroglou, an individual (each, a “Seller” and together, the “Sellers”). RECITALS WHEREAS, the Sellers own all of the issu |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 18, 2023 |
EXHIBIT 99.1 Cosmos Health Ends 2022 with Transformed Balance Sheet and Achieves Positive Adjusted EBITDA for the Fiscal Year 2022 CHICAGO, IL / ACCESSWIRE / April 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices |
|
| April 12, 2023 |
EXHIBIT 21 SUBSIDIARIES Name Jurisdiction Ownership Cosmofarm Ltd. Greece 100 % SkyPharm, S.A. Greece 100 % Decahedron Ltd. United Kingdom 100 % |
|
| April 12, 2023 |
Canada Inc Purchase Agreement dated as of January 6, 2023 (67) EXHIBIT 10.82 PURCHASE AGREEMENT (the “Agreement”) January 6, 2023 4423607 CANADA INC Owner of PLACE CHURCHILL INC 3705 Place Churchill Inc Brossard (Québec) J4Y0E4 Canada An agreement has been concluded as follows. Cosmos Health Inc. (the "Purchaser") based on the warranties and representations herein contained and subject to the terms and conditions hereinafter set forth hereby offers to purchas |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413305 (Check one:) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| March 6, 2023 |
EXHIBIT 10.1 SECURED PROMISSORY NOTE Principal Amount: € 4,100,000.00 Issue Date: February 28, 2023 For value received, Cana Laboratories Holding (Cyprus) Limited, a corporation organized under the laws of the Republic of Cyprus (the “Borrower”), hereby promises to pay to the order of Cosmos Health, Inc., a corporation organized under the laws of the state of Nevada (the “Holder”) the principal su |
|
| March 6, 2023 |
Cana Holdings Share Pledge Agreement dated as of February 28, 2023 (66) EXHIBIT 10.2 CANA HOLDINGS SHARE PLEDGE AGREEMENT THIS SHARE PLEDGE AGREEMENT is made as of this 28th day of February, 2023 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), among Konstantinos-Gaston Kanaroglou and Konstantina-Mathilde Kanaroglou, (the “Pledgors” and each a “Pledgor”), Cana Laboratories Holding (Cyprus) Limited (as defined below, hereb |
|
| March 6, 2023 |
Cana Pharmaceutical Share Pledge Agreement dated as of February 28, 2022 (66) EXHIBIT 10.3 CANA PHARMACEUTICALS SHARE PLEDGE AGREEMENT THIS SHARE PLEDGE AGREEMENT is made as of this 28th day of February, 2023 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) among Cana Laboratories Holding (Cyprus) Limited, a corporation organized under the laws of the Republic of Cyprus (the “Pledgor”) and Cosmos Health Inc., a corporation organ |
|
| February 7, 2023 |
EXHIBIT 99.1 Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer CHICAGO, IL / ACCESSWIRE / February 1, 2023 /Cosmos Health Inc.(“the Company”)(Nasdaq:COSM),a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical dev |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 30, 2023 |
COSMOS HEALTH INC. 2,567,450 Shares of Common Stock Registration Statement No. 333-269289 Filed Pursuant to Rule 424(b)(3) Under The Securities Act of 1933 PROSPECTUS COSMOS HEALTH INC. 2,567,450 Shares of Common Stock This prospectus relates to the sale (the “Offering”) by selling shareholders (the “Selling Shareholders”) of up to 2,567,450 shares of common stock, $0.001 par value (the “Shares”), of Cosmos Health Inc. (the “Company,” “Cosmos” or “ |
|
| January 25, 2023 |
COSMOS HEALTH INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 CORRESP 1 filename1.htm COSMOS HEALTH INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 January 25, 2023 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Jennie Beysolow Re: Cosmos Health Inc. Form S-3 Registration Statement File No. 333-269289 Dear Ms. Beysolow: Pursuant to Rule 461 promulgated under the Securities Act o |
|
| January 18, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) Cosmos Health Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offerin |
|
| January 18, 2023 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 18, 2023 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 18, 2023 Registration Statement No. |
|
| January 17, 2023 |
Amendment No. 1 to Securities Purchase Agreement of Grigorios Siokas (65) EXHIBIT 10.1 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This amendment (the “Amendment”) to the Securities Purchase Agreement dated as of December 19, 2022 (the “SPA”), by and between Cosmos Health Inc. (the “Company”) (f/k/a Cosmos Holdings Inc.) and Grigorios Siokas (“Siokas”), Chief Executive Officer of the Company, with addresses set forth below. WHEREAS, the Company and Siokas agreed to |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2023 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 12, 2023 |
EXHIBIT 99.1 Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands CHICAGO, IL / ACCESSWIRE / January 10, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceutical |
|
| December 23, 2022 |
US2214132068 / COSMOS HOLDINGS INC / Siokas Grigorios - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) COSMOS HOLDINGS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 221413206 (CUSIP Number) Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158 (Name, Address and Telephone Num |
|
| December 21, 2022 |
PROSPECTUS SUPPLEMENT (to the Prospectus dated December 15, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| December 20, 2022 |
EXHIBIT 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Issuance Date: December [•], 2022 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| December 20, 2022 |
Form of Securities Purchase Agreement (64) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December , 2022, between Cosmos Holdings Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| December 20, 2022 |
EXHIBIT 99.1 Cosmos Health Inc. Announces Pricing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market CHICAGO, IL / ACCESSWIRE / December 19, 2022 / Cosmos Health Inc. (the “Company”) (Nasdaq: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devic |
|
| December 20, 2022 |
Form of Placement Agency Agreement (64) EXHIBIT 10.2 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 December , 2022 Cosmos Health Inc. Attention: Grigorios Siokas, Chief Executive Officer 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 Re: Placement Agency Agreement Dear Mr. Siokas: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partne |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2022 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| December 20, 2022 |
Form of Pre-Funded Warrant (64) EXHIBIT 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Exercise Date: December , 2022 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| December 20, 2022 |
COSMOS HOLDINGS INC. Shares of Common Stock Shares of Preferred Stock Subscription Rights Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-267550 $50,000,000 COSMOS HOLDINGS INC. Shares of Common Stock Shares of Preferred Stock Warrants/Units Subscription Rights We may offer and sell the securities identified above from time to time in one or more offerings at prices and on terms that we will determine at the time of each offering, for an aggregate initial offering price |
|
| December 19, 2022 |
Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc. Announces a 1-For-25 Reverse Stock Split EXHIBIT 99.1 Cosmos Holdings Inc. Changes its Name to Cosmos Health Inc. and Announces a 1-For-25 Reverse Stock Split CHICAGO, December 16, 2022 (GLOBE NEWSWIRE) –Cosmos Holdings Inc. d/b/a Cosmos Health (“the Company") (Nasdaq: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announ |
|
| December 19, 2022 |
Certificate of Amendment to Articles of Incorporation (63) EXHIBIT 3.1 |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 16, 2022 |
COSMOS HOLDINGS INC. 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 COSMOS HOLDINGS INC. 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 December 15, 2022 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F St NW Washington, D.C. 20549 Attention: Abe Friedman / Doug Jones Re: Cosmos Holdings Inc. Form 10-K Filed April 15, 2022 File No. 001-41308 Ladies and Gentlemen: Cosmos Holdings Inc. (the “Company”) is responding to the |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-K/A ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HOLDINGS INC. (Exact |
|
| December 16, 2022 |
EX-21 2 cosmex21.htm LIST OF SUBSIDIARIES EXHIBIT 21 SUBSIDIARIES Name Jurisdiction Ownership Cosmofarm Ltd. Greece 100% SkyPharm, S.A. Greece 100% Decahedron Ltd. United Kingdom 100% |
|
| December 13, 2022 |
COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 December 13, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Janice Adeloye Re: Cosmos Holdings Inc. Form S-3 Registration Statement File No. 333-267550 Dear Ms. Adeloye: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, C |
|
| December 5, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 1, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 1, 2022 Registration Statement No. |
|
| December 1, 2022 |
Cosmos Holdings Inc. 141 West Jackson Boulevard Chicago, IL 60604 CORRESP 1 filename1.htm Cosmos Holdings Inc. 141 West Jackson Boulevard Chicago, IL 60604 December 1, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Janice Adeloye Re: Cosmos Holdings Inc. Form S-3 Registration Statement File No. 333-267550 Dear Ms. Adeloye: As counsel to Cosmos Holdings Inc. (the “Company”), we are filing |
|
| December 1, 2022 |
EX-FILING FEES 4 cosmex107.htm FILING FEE TABLE EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 16, 2022 |
Cosmos Health Reports Third Quarter 2022 Financial Results EXHIBIT 99.1 Cosmos Health Reports Third Quarter 2022 Financial Results CHICAGO, November 15, 2022 (GLOBE NEWSWIRE) – Cosmos Holdings (d/b/a Cosmos Health, Inc.) (“the Company”) (Nasdaq: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported fi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HOLDINGS INC. (Exact name of registrant |
|
| November 7, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 7, 2022 S-3/A 1 cosms3.htm FORM S-3/A AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 7, 2022 Registration Statement No. 333-267550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3/A (AMENDMENT NO. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COSMOS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Nevada 5122 27-0611758 (St |
|
| November 4, 2022 |
US2214132068 / COSMOS HOLDINGS INC / Kolefas Athanasios - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 COSMOS HOLDINGS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 221413206 (CUSIP Number) Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158 (Name, Address and Telephone Number of Person Auth |
|
| October 25, 2022 |
US2214132068 / COSMOS HOLDINGS INC / Siokas Grigorios - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) COSMOS HOLDINGS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 221413206 (CUSIP Number) Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158 (Name, Address and Telephone Num |
|
| October 20, 2022 |
Registration Statement No. 333-267505 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-267917 Filed Pursuant to Rule 462(b) PROSPECTUS COSMOS HOLDINGS INC. $7,500,000 62,500,000 Shares of Common Stock 62,500,000 Pre-Funded Warrants 125,000,000 Common Warrants We are offering on a “reasonable best efforts” basis up to $7,500,000 of shares of common stock of Cosmos Holdings Inc. (the |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 18, 2022 |
Form of Series B Common Warrant (62) EXHIBIT 4.3 SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Issuance Date: October [?], 2022 THIS SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| October 18, 2022 |
Form of Pre-Funded Warrant (62) EXHIBIT 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Exercise Date: October , 2022 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| October 18, 2022 |
Form of Securities Purchase Agreement (62) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October [ ], 2022, between Cosmos Holdings Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| October 18, 2022 |
Form of Series A Common Warrant (62) EXHIBIT 4.2 SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Issuance Date: October [?], 2022 THIS SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| October 17, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 18, 2022 S-1MEF 1 cosms1.htm FORM S-1MEF AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 18, 2022 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COSMOS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Nevada 5122 27-0611758 (State or other jurisdictio |
|
| October 17, 2022 |
EX-FILING FEES 4 cosmex107.htm FILING FEE TABLE EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum |
|
| October 14, 2022 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 CORRESP 1 filename1.htm A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 October 14, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attn: Janice Adeloye Re: Cosmos Holdings Inc. Registration Statement on Form S-1 Filed September 19, 2022, as amende |
|
| October 14, 2022 |
COSMOS HOLDINGS, INC. 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 COSMOS HOLDINGS, INC. 141 West Jackson Boulevard, Suite 4236 Chicago, Illinois 60604 October 14, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye Re: Cosmos Holdings, Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: On behalf of Cosmos Holdings, Inc., we are requesting that you with |
|
| October 14, 2022 |
WRITER'S DIRECT: (646) 428-3210 WRITER'S DIRECT: (646) 428-3210 E-MAIL: [email protected] October 14, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye Re: Cosmos Holdings, Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: As counsel to Cosmos Holdings, Inc., we are requesting that you withdraw the Company?s request |
|
| October 14, 2022 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 CORRESP 1 filename1.htm A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 October 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attn: Janice Adeloye Re: Cosmos Holdings Inc. Registration Statement on Form S-1 Filed September 19, 2022, as amende |
|
| October 14, 2022 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 CORRESP 1 filename1.htm A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 October 14, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attn: Janice Adeloye Re: Cosmos Holdings Inc. Registration Statement on Form S-1 Filed September 19, 2022, as amende |
|
| October 14, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 14, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 14, 2022 Registration Statement No. |
|
| October 14, 2022 |
COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 October 14, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Janice Adeloye Re: Cosmos Holdings Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Co |
|
| October 14, 2022 |
COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 October 14, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Janice Adeloye Re: Cosmos Holdings Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Co |
|
| October 13, 2022 |
Calculation of Filing Fee Table** EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| October 13, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 13, 2022 S-1/A 1 cosms1a.htm FORM S-1/A AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 13, 2022 Registration Statement No. 333-267505 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1/A (Amendment No. 2) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COSMOS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Nevada 5122 27-0611758 (S |
|
| October 12, 2022 |
WRITER'S DIRECT: (646) 428-3210 E-MAIL: [email protected] October 12, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye Re: Cosmos Holdings, Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: As counsel to Cosmos Holdings, Inc. (the ?Company?), we are requesting that you withdraw the Co |
|
| October 12, 2022 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 October 12, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attn: Janice Adeloye Re: Cosmos Holdings Inc. Registration Statement on Form S-1 Filed September 19, 2022, as amended File No. 333-267505 Ac |
|
| October 11, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 11, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 11, 2022 Registration Statement No. |
|
| October 11, 2022 |
Form of Placement Agency Agreement (61) EX-1.1 2 cosmex11.htm FORM OF PLACEMENT AGENCY AGREEMENT EXHIBIT 1.1 [AGP Letterhead] October , 2022 Cosmos Holdings Inc. Attention: Grigorios Siokas, Chief Executive Officer 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 Re: Placement Agency Agreement Dear Mr. Siokas: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as t |
|
| October 11, 2022 |
Form of Pre-Funded Warrant (61) EXHIBIT 4.4 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Exercise Date: October , 2022 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| October 11, 2022 |
Form of Securities Purchase Agreement (61) EXHIBIT 4.6 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October [?], 2022, between Cosmos Holdings Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions se |
|
| October 11, 2022 |
EXHIBIT 4.5 SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK COSMOS HOLDINGS INC. Warrant Shares: Original Issuance Date: October [?], 2022 THIS SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| October 11, 2022 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 October 11, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attn: Janice Adeloye Re: Cosmos Holdings Inc. Registration Statement on Form S-1 Filed September 19, 2022, as amended File No. 333-267505 Ac |
|
| October 11, 2022 |
COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 COSMOS HOLDINGS INC. 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 October 11, 2022 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Janice Adeloye Re: Cosmos Holdings Inc. Form S-1 Registration Statement File No. 333-267505 Dear Ms. Adeloye: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Co |
|
| October 11, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant?s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| October 3, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| October 3, 2022 |
Form of Warrant Exchange Agreement (60) EXHIBIT 4.2 WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (the ?Agreement?) is entered into as of the day of October, 2022, by and among Cosmos Holdings Inc., a Nevada corporation with offices located at 141 West Jackson Blvd, Suite 4236, Chicago, Illinois 60604 (the ?Company?), and the undersigned holder of the Existing Warrant (as defined below) (the ?Holder?), with reference to the |
|
| October 3, 2022 |
EXHIBIT 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 27, 2022 |
Company Presentation dated September 2022. EX-99.1 2 cosmex991.htm COMPANY PRESENTATION EXHIBIT 99.1 |
|
| September 23, 2022 |
Omnibus Equity Incentive Plan (49) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| September 21, 2022 |
EX-FILING FEES 4 cosmex107.htm FILING FEE TABLE EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum |
|
| September 21, 2022 |
Power of attorney (included on the signature page)*** AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 21, 2022 Registration Statement No. |
|
| September 21, 2022 |
EXHIBIT 1.2 COSMOS HOLDINGS INC. COMMON STOCK SALES AGREEMENT September 15, 2022 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Cosmos Holdings Inc., a Nevada corporation (the ?Company?), confirms its agreement (this ?Agreement?) with A.G.P./Alliance Global Partners, as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time |
|
| September 19, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 19, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 19, 2022 Registration Statement No. |
|
| September 19, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Cosmos Holdings Inc. (Exact Name of Registrant as Specified in its Charter) N/A (Translation of Registrant?s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| September 19, 2022 |
Form of Placement Agent Agreement (57) EX-1.1 2 cosmex11.htm FORM OF PLACEMENT AGENT AGREEMENT EXHIBIT 1.1 [AGP Letterhead] September 15, 2022 Cosmos Holdings Inc. Attention: Grigorios Siokas, Chief Executive Officer 141 West Jackson Blvd., Suite 4236 Chicago, IL 60604 Re: Placement Agency Agreement Dear Mr. Siokas: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, a |
|
| August 23, 2022 |
EXHIBIT 99.1 Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 CHICAGO, August 22, 2022 (GLOBE NEWSWIRE) - Cosmos Health, Inc. (?the Company") (Nasdaq: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a |
|
| August 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 22, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-54436 COSMOS HOLDINGS INC. (Exact name of registrant as sp |
|
| August 16, 2022 |
NT 10-Q 1 cosmnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54436 CUSIP Number: 221413206 (Check one:) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition R |
|
| August 4, 2022 |
US2214132068 / COSMOS HOLDINGS INC / Siokas Grigorios - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) COSMOS HOLDINGS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 221413206 (CUSIP Number) Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158 (Name, Address and Telephone Numb |
|
| July 29, 2022 |
EXHIBIT 3(i) COSMOS HOLDINGS INC. AMENDMENT TO CERTIFICATE OF DESIGNATIONS OF RIGHTS AND PREFERENCES OF SERIES A CONVERTIBLE PREFERRED STOCK July 25, 2022 Pursuant to Section 78.1955 of the Nevada Revised Statutes (the ?NRS?), Cosmos Holdings Inc. (the ?Corporation?) hereby certifies that: WHEREAS, Section 3 of the Articles of Incorporation of the Corporation, as amended (the ?Articles of Incorpor |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 29, 2022 |
EXHIBIT 99.1 Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company?s Evolution into an Innovative Global Healthcare Group, Driven by One Purpose: Improving People?s Lives CHICAGO, July 29, 2022 - Cosmos Holdings, Inc. (?the Company?) (Nasdaq: COSM) announced today that it is changing the name of the Company to Cosmos Health to better reflect the Company?s evolution into an inn |
|
| July 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 25, 2022 |
EXHIBIT 99.1 Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928;Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands CHICAGO, July 20, 2022 - Cosmos Holdings, Inc. (?the Company") (Nasdaq: COSM), an international pharmaceutical company with a proprietary line of n |
|
| July 25, 2022 |
Binding Letter of Intent with Pharmaceutical Laboratories Cana, S.A. dated July 19, 2022 (56) EXHIBIT 10.1 BINDING LETTER OF INTENT (LOI) This Letter of Intent (?LOI?) sets forth the terms and conditions for a proposed acquisition and financing by Cosmos Holdings, Inc. (?Cosmos?), a corporation organized under the laws of the State of Nevada, with Company I.R.S number (27-0611758),located at 141 West Jackson Boulevard, Suite 4236, Chicago, IL 60604, of Pharmaceutical Laboratories Cana S.A. |
|
| June 7, 2022 |
As filed with the Securities and Exchange Commission on June 7, 2022 As filed with the Securities and Exchange Commission on June 7, 2022 Registration No. |
|
| June 2, 2022 |
Cosmos Holdings Inc. 141 West Jackson Blvd. Suite 4236 Chicago, 60604, IL (312) 536-3102 CORRESP 1 filename1.htm Cosmos Holdings Inc. 141 West Jackson Blvd. Suite 4236 Chicago, 60604, IL (312) 536-3102 June 2, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Andrew Weiner Re: Cosmos Holdings Inc. Registration Statement on Form S-1 File No. 333-265190 Request for Acceleratio |
|
| May 25, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 25, 2022 |
Calculation of SEC Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Cosmos Holdings, Inc. |
|
| May 18, 2022 |
EXHIBIT 99.1 Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022 Reports positive net income of $0.2 million and $1.2 million of EBITDA for the first quarter of 2022 CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) - Cosmos Holdings, Inc. (?the Company") (Nasdaq: COSM), an international pharmaceutical company with a propr |
|
| May 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2022 Cosmos Holdings Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Num |
